ARDELYX, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ARDELYX, INC. (ARDX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$90.10 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2021-03-08
- ARDELYX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$75.24M, a 667.06% decline year-over-year.
- ARDELYX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was $13.27M.
- ARDELYX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$90.10M, a 188.02% decline from fiscal 2019.
- ARDELYX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was $102.36M, a 2924.08% increase from fiscal 2018.
- ARDELYX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was $3.38M, a 331.21% increase from fiscal 2017.
- ARDELYX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2017 was $785.00K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$90.10M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | -$90.12M 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | -$80.64M 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | -$75.24M 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $102.36M 10-K · filed 2021-03-08 | |||
| 2019-09-30 | $13.90M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $10.86M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $13.27M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $3.38M 10-K · filed 2021-03-08 | |||
| 2018-09-30 | -$368.00K 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $16.37M 10-Q · filed 2019-08-09 | |||
| 2017-12-31 | $785.00K 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |